肥胖与射血分数降低的心力衰竭:综述
本综述探讨肥胖与射血分数降低的心力衰竭(HFrEF)的共存关系,指出多数HFrEF患者超重或肥胖,但肥胖在HFrEF中研究有限。肥胖可能作为可修饰的疾病放大器影响HFrEF进展,而非主要病因驱动因素。减重干预在HFrEF中的证据有限,尚无新型减重药物在HFrEF患者中专门评估。
要点
- 多数HFrEF患者超重或肥胖,但肥胖在HFrEF中研究少于HFpEF。
- 肥胖可能作为可修饰的疾病放大器影响HFrEF进展,而非主要病因。
- 减重干预在HFrEF中证据有限,新型减重药物未在HFrEF中专门评估。
核心结论
- 肥胖在HFrEF中可能应被视为可修饰的疾病放大器,影响疾病进展和临床轨迹,而非主要病因驱动因素。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- 大多数HFrEF患者超重或伴有肥胖。
- 肥胖与HFrEF的关系较肥胖与HFpEF的关系表征更不充分。
- BMI作为肥胖替代标志物存在局限性,且肥胖悖论现象使HFrEF中BMI与结局的关系复杂化。
- 减重干预(如肥胖药物治疗)在肥胖合并HFpEF患者中已显示安全性和有效性。
- HFrEF中证据有限,主要来自非肥胖聚焦的试验且存在方法学限制。
临床怎么用
- 在HFrEF患者中应关注肥胖作为可修饰因素对疾病进展的影响。
- 减重干预在HFrEF中的应用需谨慎,因证据有限且主要来自非肥胖聚焦试验。
局限性
- HFrEF中证据有限,主要来自非肥胖聚焦的试验且存在方法学限制。
- BMI作为肥胖替代标志物存在局限性。
- 肥胖悖论现象使HFrEF中BMI与结局的关系复杂化。
- 尚无新型减重药物在HFrEF患者中专门评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obesity and heart failure with reduced ejection fraction (HFrEF) frequently coexist. In fact, most patients with HFrEF are overweight or have concomitant obesity. However, despite this high prevalence, obesity in HFrEF has received limited attention as most recent reviews have concentrated on heart failure broadly or on the heart failure with preserved ejection fraction (HFpEF) phenotype. This limited attention may, in part, be attributed to the stronger and more consistent pathophysiological and epidemiologic associations observed between obesity and HFpEF, whereas the relationship between obesity and HFrEF remains less well characterized. Much of this uncertainty reflects inconsistent findings across studies regarding whether body mass index independently predicts incident HFrEF, given its well-recognized limitations as a surrogate marker of adiposity. These challenges are further compounded by the phenomenon known as the obesity paradox in patients with HFrEF, in which higher body mass index is often associated with better outcomes. Nonetheless, in HFrEF, obesity may be better conceptualized as a modifiable disease amplifier that influences disease progression and clinical trajectory, rather than a primary etiologic driver. Weight loss interventions such as obesity pharmacotherapy have demonstrated safety and efficacy in patients with obesity and HFpEF, where obesity-related pathophysiologic processes including systemic inflammation, neurohormonal activation, local paracrine signaling, and mechanical loading are well-described contributors to disease development. Although the relative contribution of these processes may differ in HFrEF, excess adiposity may still exacerbate disease progression through these pathways, suggesting potential applicability of weight loss interventions in this population. To date, evidence in HFrEF remains limited and is derived largely from non-obesity-focused trials with methodological constraints. Despite the development of several novel weight loss agents, none are being specifically evaluated in patients with HFrEF, limiting understanding of their potential clinical impact in these patients.
引用
- Khan MS, Javaid SS, Petrie MC, et al. Obesity and Heart Failure With Reduced Ejection Fraction: A Review. J Am Coll Cardiol. 2026. PMID: 41949514. doi:10.1016/j.jacc.2026.02.5083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。